Abbott agreed to acquire Exact Sciences for roughly $23 billion, a strategic move to position Abbott in cancer screening, treatment selection and recurrence monitoring. The deal brings Cologuard, Oncotype Dx and other oncology testing assets under Abbott’s diagnostics umbrella, expanding its addressable market and product portfolio. Analysts called the transaction a landmark for central‑lab and single‑site diagnostics consolidation, arguing it validates the commercial maturity of high‑value oncology testing businesses. The acquisition will prompt integration planning around reimbursement, lab operations and cross‑selling opportunities across Abbott’s global channels.